Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our medical information is accurate, up to date, and scientifically balanced.

DEPO-SUBQ PROVERA 104®(medroxyprogesterone acetate)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our medical information is accurate, up to date, and scientifically balanced.

DEPO-SUBQ PROVERA 104® Quick Finder

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the...
Did you find an answer to your question? Yes No

WARNING: LOSS OF BONE MINERAL DENSITY

  • Women who use depo-subQ provera 104 may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely...
Did you find an answer to your question? Yes No

1 INDICATIONS AND USAGE

Depo-subQ provera 104 is indicated in females of reproductive age for:

  • Prevention of pregnancy and
  • Management of endometriosis-associated pain.
...
Did you find an answer to your question? Yes No

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosage and Administration Instructions

Depo-subQ provera 104 is only for subcutaneous administration and is only to be...

Did you find an answer to your question? Yes No

3 DOSAGE FORMS AND STRENGTHS

Injectable suspension (104 mg/0.65 mL) in a single-dose pre-filled syringe, packaged with a 26-gauge × 3/8-inch Terumo SurGuard® needle.

Did you find an answer to your question? Yes No

4 CONTRAINDICATIONS

The use of depo-subQ provera 104 is contraindicated in the following conditions:

  • Active thrombophlebitis, or current or history of thromboembolic disorders, or cerebral vascular...
Did you find an answer to your question? Yes No

5 WARNINGS AND PRECAUTIONS

5.1 Loss of Bone Mineral Density

Use of depo-subQ provera 104 reduces serum estrogen levels and is associated with significant loss of bone...

Did you find an answer to your question? Yes No

6 ADVERSE REACTIONS

The following important adverse reactions are described in more detail in other sections of the prescribing information:

  • Loss of bone mineral density [see...
Did you find an answer to your question? Yes No

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on Depo-subQ provera 104

Moderate or Strong...

Did you find an answer to your question? Yes No

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

There is no use for depo-subQ provera 104 in pregnancy and therefore depo-subQ provera 104 should be discontinued during...

Did you find an answer to your question? Yes No

11 DESCRIPTION

Depo-subQ provera 104 contains medroxyprogesterone acetate (MPA), a derivative of progesterone, as its active ingredient. MPA is a white to off-white, odorless crystalline powder that is stable in air and that...

Did you find an answer to your question? Yes No

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Depo-subQ provera 104 inhibits the secretion of gonadotropins, which primarily prevents follicular maturation and...

Did you find an answer to your question? Yes No

14 CLINICAL STUDIES

14.1 Contraception Studies

In three open label clinical studies, depo-SubQ provera 104 (104 mg given every three months subcutaneously), was...

Did you find an answer to your question? Yes No

15. REFERENCES

  1. Li CI, Beaber EF, Tang MCT et al. Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 years of Age. Cancer Research 2012; 72:2028-2035.
  2. Paul C, Skegg DCG, Spears GFS. Depot...
Did you find an answer to your question? Yes No

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Depo-subQ provera 104 medroxyprogesterone acetate injectable suspension (104 mg/0.65 mL) is available in a...

Did you find an answer to your question? Yes No

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

...

Did you find an answer to your question? Yes No

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

...

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event